Quick Answer
Definium Therapeutics, Inc. reported R&D Expense of $117.67 million for fiscal year 2025.
Definium Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $117.67M | +80.2% |
| 2024 | $65.30M | +25.3% |
| 2023 | $52.12M | +44.1% |
| 2022 | $36.17M | +4.0% |
| 2021 | $34.79M | +86.7% |
| 2020 | $18.63M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $30.98M | +80.2% | +3.9% |
| June 30, 2025 | $29.81M | +103.5% | +27.6% |
| March 31, 2025 | $23.36M | +99.5% | +35.9% |
| September 30, 2024 | $17.19M | +30.2% | +17.4% |
| June 30, 2024 | $14.64M | -0.9% | +25.1% |
| March 31, 2024 | $11.71M | -7.1% | -11.3% |
| September 30, 2023 | $13.20M | +69.9% | -10.7% |
| June 30, 2023 | $14.78M | +58.4% | +17.3% |
- Definium Therapeutics, Inc. showed an increase of +80.2% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Definium Therapeutics, Inc.’s r&d expense has grown by 531.6% (from $18.63 million to $117.67 million).
- The most recent figure is from Definium Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: